RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS
Clinical trials for RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare protein disease: experimental drug targets relapsed amyloidosis
Disease control Recruiting nowThis study tests an experimental drug called linvoseltamab in 220 people with AL amyloidosis that has returned or not improved after prior therapy. The drug aims to reduce abnormal proteins that damage organs like the heart and kidneys. The trial first finds the safest dose, then…
Matched conditions: RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take aim at rare Organ-Damaging disease
Disease control Recruiting nowThis early-phase trial tests a personalized cell therapy called BCMA-targeted CAR-T cells in 30 adults with relapsed or refractory light chain amyloidosis, a rare disease where abnormal proteins build up in organs. The treatment uses the patient's own immune cells, modified to at…
Matched conditions: RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS
Phase: EARLY_PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC